Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07462442) titled 'Study of QLS5308 in Patients With Advanced Solid Tumors' on March 5.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Qilu Pharmaceutical Co., Ltd.

Condition: Metastatic Solid Tumors

Intervention: Drug: QLS5308 IV infusion

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: March 28, 2026

Target Sample Size: 192

To know more, visit https://clinicaltrials.gov/study/NCT07462442

Published by HT Digital Content Services with permission from Health Daily Dige...